Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Eric E Lloyd"'
Autor:
John W. Gaubatz, Baiba K. Gillard, John B. Massey, Ron C. Hoogeveen, Max Huang, Eric E. Lloyd, Joe L. Raya, Chao-yuh Yang, Henry J. Pownall
Publikováno v:
Journal of Lipid Research, Vol 48, Iss 2, Pp 348-357 (2007)
Small, dense, electronegative low density lipoprotein [LDL(−)] is increased in patients with familial hypercholesterolemia and diabetes, populations at increased risk for coronary artery disease. It is present to a lesser extent in normolipidemic s
Externí odkaz:
https://doaj.org/article/f59d7208b17c4167aed198eb74ece991
Autor:
Dennis J. Faix, Eric E. Lloyd, Paul M. Mendelman, Astrid Borkowski, Mengya Liu, John Boslego, Ashley Jackson, James Sherwood
Publikováno v:
Vaccine. 38(41)
Background We performed this first-in-human efficacy trial of Takeda’s bivalent norovirus vaccine candidate (TAK-214) against moderate or severe acute gastroenteritis (AGE) in healthy adults. Methods This double-blind, randomized, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87462ff0ad7dadabc1c5065f54715b93
https://pubmed.ncbi.nlm.nih.gov/32878708
https://pubmed.ncbi.nlm.nih.gov/32878708
Autor:
Eric E. Lloyd, Keith C. Ferdinand, Michael A. Weber, Jingtao Wu, William C. Cushman, George L. Bakris, William B. White
Publikováno v:
The American Journal of Cardiology. 122:1496-1505
Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b41d7e24f346b020ca7960ea4a05407b
https://doi.org/10.1016/j.amjcard.2018.07.022
https://doi.org/10.1016/j.amjcard.2018.07.022
Autor:
Stuart Kupfer, Eric E. Lloyd, Enrico Agabiti-Rosei, Lin Zhao, Attila Juhasz, Mark J. Caulfield, David Collier, Michie Hisada
Publikováno v:
J Clin Hypertens (Greenwich)
Patients with grade 2‐3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160‐190 mm Hg and 24‐hour SBP 140‐175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL‐M)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c56b3fd8088f730b84f10bc67a40551
https://doi.org/10.1111/jch.13376
https://doi.org/10.1111/jch.13376
Autor:
William C. Cushman, Stuart Kupfer, Eric E. Lloyd, Andrew V. Roberts, Domenic A. Sica, George L. Bakris, Michael A. Weber, William B. White
Publikováno v:
Journal of Hypertension
Background: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). Objective/methods: We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b0ca70f8cc3e70f46b564bc8885d22
https://doi.org/10.1097/hjh.0000000000001647
https://doi.org/10.1097/hjh.0000000000001647
Publikováno v:
J Clin Hypertens (Greenwich)
This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs fixed-dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c548ee37ec467c811ecf8befe2b77446
https://doi.org/10.1111/jch.13009
https://doi.org/10.1111/jch.13009
Publikováno v:
Clinical and Experimental Hypertension
This 56-week phase 3, open-label, treat-to-target study, involving 2 consecutive, non-randomized cohorts, evaluated the safety and tolerability of azilsartan medoxomil (AZL-M) in essential hypertension (mean baseline blood pressure [BP] 152/100 mmHg)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dee9fed8b5cc68f571e4f0ed785c02d8
http://europepmc.org/articles/PMC4819839
http://europepmc.org/articles/PMC4819839
Publikováno v:
Journal of Hypertension
Background: Angiotensin receptor blockers (ARBs) are preferred antihypertensive therapies in patients with type 2 diabetes mellitus (T2DM). Azilsartan medoxomil (AZL-M) is a potent ARB for the treatment of stages 1-2 hypertension. We compared the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26645a6905e8d9347d90cb1733b8659d
http://europepmc.org/articles/PMC4947533
http://europepmc.org/articles/PMC4947533
Publikováno v:
Journal of Clinical Hypertension (Greenwich, Conn.)
A phase 3, 26-week, open-label, titrate-to-target study (n=418) assessed the safety of azilsartan medoxomil (AZL-M) alone and with chlorthalidone (CLD), followed by a 6-week, double-blind, placebo-controlled reversal phase with change in clinic diast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa40b4d137e8d3d250c346af317d339
http://europepmc.org/articles/PMC5024056
http://europepmc.org/articles/PMC5024056
Autor:
Lin Zhao, Suzanne Oparil, Attila Juhasz, George L. Bakris, Michie Hisada, Stuart Kupfer, Eric E. Lloyd
Publikováno v:
J Clin Hypertens (Greenwich)
An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::128360c6dd3a8ec328cc40f5458de779
https://pubmed.ncbi.nlm.nih.gov/29504233
https://pubmed.ncbi.nlm.nih.gov/29504233